Lanean...
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
Lung cancer is the leading cause of cancer-related mortality in both sexes, accounting for over one quarter of cancer deaths. Non-small-cell lung cancer (NSCLC) comprises 85%–90% of lung cancer diagnoses and despite advances in multimodality therapies, 5-year survival rates remain dismal with a medi...
Gorde:
| Argitaratua izan da: | Onco Targets Ther |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4408973/ https://ncbi.nlm.nih.gov/pubmed/25945060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S67262 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|